Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(5)

Summary:

TNFα inhibitors have made brilliant achievements since the launch of the first relevant monoclonal antibody, owing to the approval of multiple indications on the autoimmune drug market; and in 2012, Humira became the sales champion to rise to fame, and the peak sales of Enbrel and Remicade also approached USD 10 billion, making TNFα inhibitors second to none on this drug market.

However, as patents of those three monoclonal antibodies expired, Enbrel and Remicade have suffered impacts from generic drugs, and Humira’s dominance is worse than before due to patent litigation and cooperation postponement.

The markets of Simponi/Simponi Aria and Cimzia separately launched by J & J and UCB were barely satisfactory, which are difficult to continue the overwhelming market momentum of the above monoclonal antibodies.

On the RA drug market, the share of TNFα inhibitors continued to decline due to challenges from BMS’ Orencia, Roche’s anti-IL-6 monoclonal antibody, and Pfizer’s JAK inhibitor Xeljanz.

Wherein, the small-molecule JAK inhibitors have showed preliminary advantages in the new round of competition, to become the biggest growth driver of RA drug market.

TNFα plays a greater role than interleukin in abnormal immune responses, however, anti-TNFα monoclonal antibodies are inferior to IL inhibitors in treating psoriasis.

J & J’s anti-IL-12/23 Stelara marketed in 2009 has been maintaining rapid growth, with sales even reaching USD 4 billion in 2017.

However, Novartis’ anti-IL-17A monoclonal antibody: Cosentyx beat Stelara in the clinical head-to-head study, and is expected to replace the latter to become a benchmark on the psoriasis drug market.

But J & J did not await the doom. It launched the first anti-IL-23 monoclonal antibody: guselkumab in 2017 in reply.

The entire psoriasis drug market has entered a new round of intense seesaw battle.

Back to read:

Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(4)

Register as Visitor to CPhI China 2018!